Pathogenesis(pgns) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Pathogenesis(pgns)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: John Ritter who wrote (161)	3/24/1999 9:31:00 AM
From: Biomaven	Read Replies (2) of 228

John, Is PGNS a good buy at 12? Historically, biotechs that have cratered have not done well, though there have certainly been exceptions like CNTO and MEDI. The trouble here is that they now have no credibility, and it's going to be a long, hard struggle back. The coming lawsuits won't help either. If their existing US market is indeed close on saturated (not really clear yet), a lot will depend on the results of their new trials. On the plus side, at these prices they are a clear takeover candidate; they have plenty of cash and would be clearly profitable if they weren't running new trials. I still have a very small stake left that I'm holding for now. Peter

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next